[Studies on the pharmacokinetics of the compound preparation sulfamerazine/trimethoprim (Berlocombin-200) in pregnancy].
Pharmacokinetics of the sulphamerazine/trimethoprim-combination Berlocombin-200 was calculated by an one-compartment-model following therapeutic administration in pregnant women and compared with a control group. Distribution parameters are significantly changed, but elimination half-lifes of both the sulphonamide and trimethoprim are not influenced by repeated administration during pregnancy. There are no consequences concerning the dosage of Berlocombin in bacterial infections during pregnancy.
D004338:Drug Combinations / Q000378:metabolism; D005260:Female; D006207:Half-Life; D006801:Humans; D007700:Kinetics; D011247:Pregnancy; D013416:Sulfamerazine / Q000378:metabolism*; D014295:Trimethoprim / Q000378:metabolism*; D000096926:Benzenesulfonamides
D004338:Drug Combinations; D013416:Sulfamerazine; D014295:Trimethoprim; C014230:trimerazine; D000096926:Benzenesulfonamides
Untersuchungen zur Pharmakokinetik mit dem Kombinationspräparat Sulfamerazin/Trimethoprim (Berlocombin-200) in der Schwangerschaft.